Skip to main content

Tecfidera FDA Approval History

FDA Approved: Yes (First approved March 27, 2013)
Brand name: Tecfidera
Generic name: dimethyl fumarate
Dosage form: Delayed-Release Capsules
Previous Name: BG-12
Company: Biogen Inc.
Treatment for: Multiple Sclerosis

Tecfidera (dimethyl fumarate) is an oral Nrf2 pathway activator for the treatment of relapsing forms of multiple sclerosis.

Development timeline for Tecfidera

DateArticle
Mar 27, 2013Approval FDA Approves Tecfidera - a New Treatment for Multiple Sclerosis
Oct 18, 2012Biogen Idec Receives Notification of PDUFA Date Extension
May  9, 2012US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
Feb 28, 2012Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis

See also

Tecfidera (dimethyl fumarate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer